Signifiant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge

Victor Serebruany, Vasily Cherepanov, Alexander Dukhanin

Research output: Contribution to journalArticle

Abstract

The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.

Original languageEnglish (US)
Pages (from-to)7-8
Number of pages2
JournalThrombosis and Haemostasis
Volume114
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Myocardial Reperfusion
Ambulances
Stents
Ticagrelor
Coronary Vessels
Thrombosis
Odds Ratio
Mortality
(1,2-diamino-4-nitrobenzene)dichloroplatinum(II)
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Hematology

Cite this

Signifiant excess of early deaths after prehospital ticagrelor : The ATLANTIC trial challenge. / Serebruany, Victor; Cherepanov, Vasily; Dukhanin, Alexander.

In: Thrombosis and Haemostasis, Vol. 114, No. 1, 2015, p. 7-8.

Research output: Contribution to journalArticle

Serebruany, Victor ; Cherepanov, Vasily ; Dukhanin, Alexander. / Signifiant excess of early deaths after prehospital ticagrelor : The ATLANTIC trial challenge. In: Thrombosis and Haemostasis. 2015 ; Vol. 114, No. 1. pp. 7-8.
@article{3a5b0c1088884ff48df9fe06f0d52ee6,
title = "Signifiant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge",
abstract = "The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.",
author = "Victor Serebruany and Vasily Cherepanov and Alexander Dukhanin",
year = "2015",
doi = "10.1160/TH14-11-0936",
language = "English (US)",
volume = "114",
pages = "7--8",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - Signifiant excess of early deaths after prehospital ticagrelor

T2 - The ATLANTIC trial challenge

AU - Serebruany, Victor

AU - Cherepanov, Vasily

AU - Dukhanin, Alexander

PY - 2015

Y1 - 2015

N2 - The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.

AB - The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.

UR - http://www.scopus.com/inward/record.url?scp=84934783769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934783769&partnerID=8YFLogxK

U2 - 10.1160/TH14-11-0936

DO - 10.1160/TH14-11-0936

M3 - Article

C2 - 25947272

AN - SCOPUS:84934783769

VL - 114

SP - 7

EP - 8

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -